Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
News|Articles|September 28, 2026
Q&A: Cutlip on the SELUTION SLR DEB’s FDA Approval for Coronary In-Stent Restenosis
Author(s)Donald Cutlip, MD
Fact checked by: Ryan Livingston
Donald Cutlip, MD, discusses the sirolimus balloon’s approval and its role in clinical practice for patients with ISR.
Advertisement
Advertisement
On September 21, 2026, the
Related to this article
Lasker Award winners Takehisa Kitazawa and Tomoyuki Igawa discuss prophylaxis gains, remaining unmet needs, and lessons for drug discovery.
Lasker Award winners Kunihiro Hattori, Takehisa Kitazawa, and Tomoyuki Igawa recount the 2400 variants behind the drug.
Weltruza requires no loading doses, oral supplementation, or post-injection monitoring, with approval based on the phase 3 SOLARIS trial.
Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Ryaltris pediatric approval, lonvo-z and deucrictibant HAE filings, PVX108 Fast Track, and Palforzia's exit headline Q3 2026 allergy news.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Advertisement
Advertisement